Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

n-3 PUFA Esterified to Glycerol or as Ethyl Esters Reduce Non-Fasting Plasma Triacylglycerol in Subjects with Hypertriglyceridemia: A Randomized Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Molecular characterization of microvesicular and macrovesicular steatosis shows widespread differences in metabolic pathways

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of dietary FA and energy restriction on plasma leptin and ob gene expression in mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Normalværdier for blodprøveanalyser hos gravide og fødende

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiUndervisningpeer review

  4. Polygenic predisposition to breast cancer and the risk of coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

To date, treatment of hypertriglyceridemia with long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) has been investigated solely in fasting and postprandial subjects. However, non-fasting triacylglycerols are more strongly associated with risk of cardiovascular disease. The objective of this study was to investigate the effect of long-chain n-3 PUFA on non-fasting triacylglycerol levels and to compare the effects of n-3 PUFA formulated as acylglycerol (AG-PUFA) or ethyl esters (EE-PUFA). The study was a double-blinded randomized placebo-controlled interventional trial, and included 120 subjects with non-fasting plasma triacylglycerol levels of 1.7-5.65 mmol/L (150-500 mg/dL). The participants received approximately 3 g/day of AG-PUFA, EE-PUFA, or placebo for a period of eight weeks. The levels of non-fasting plasma triacylglycerols decreased 28 % in the AG-PUFA group and 22 % in the EE-PUFA group (P < 0.001 vs. placebo), with no significant difference between the two groups. The triacylglycerol lowering effect was evident after four weeks, and was inversely correlated with the omega-3 index (EPA + DHA content in erythrocyte membranes). The omega-3 index increased 63.2 % in the AG-PUFA group and 58.5 % in the EE-PUFA group (P < 0.001). Overall, the heart rate in the AG-PUFA group decreased by three beats per minute (P = 0.045). High-density lipoprotein (HDL) cholesterol increased in the AG-PUFA group (P < 0.001). Neither total nor non-HDL cholesterol changed in any group. Lipoprotein-associated phospholipase A2 (LpPLA2) decreased in the EE-PUFA group (P = 0.001). No serious adverse events were observed. Supplementation with long-chain n-3 PUFA lowered non-fasting triacylglycerol levels, suggestive of a reduction in cardiovascular risk. Regardless of the different effects on heart rate, HDL, and LpPLA2 that were observed, compared to placebo, AG-PUFA, and EE-PUFA are equally effective in reducing non-fasting triacylglycerol levels.

OriginalsprogEngelsk
TidsskriftLipids
Vol/bind50
Udgave nummer2
Sider (fra-til)165-75
Antal sider11
ISSN0024-4201
DOI
StatusUdgivet - feb. 2015

ID: 44921458